Azithromycin for COVID-19 Treatment in Outpatients Nationwide (ACTION)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04332107 |
Recruitment Status :
Terminated
(Futility)
First Posted : April 2, 2020
Results First Posted : September 9, 2021
Last Update Posted : March 2, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID-19 SARS-CoV-2 | Drug: Azithromycin Drug: Placebos | Phase 3 |
Identification of a safe, effective treatment for individuals with mild or moderate COVID-19 that prevents disease progression and reduces hospitalization would reduce the burden on the health system. High dose hydroxychloroquine is being evaluated for SARS-CoV-2 prevention and COVID-19 disease treatment, but has a high risk of a number of potentially severe adverse events. Recent evidence has indicated that the broad-spectrum macrolide azithromycin may have some activity against coronaviruses. Here we propose an individually-randomized, placebo-controlled trial to determine the efficacy of a single dose of azithromycin for prevention of COVID-19.
Potential participants will undergo remote eligibility screening with study staff prior to enrollment. Upon determination of eligibility and signing electronic informed consent documents, participants will be emailed baseline study forms and will be mailed their randomized study treatment. At the end of the study (21 days), participants will be emailed a final study questionnaire. Note that there will no contact between study staff and participants in this trial, minimizing risk of infection spread.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 263 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19 |
Actual Study Start Date : | May 22, 2020 |
Actual Primary Completion Date : | March 16, 2021 |
Actual Study Completion Date : | March 30, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Azithromycin
1.2g of oral azithromycin
|
Drug: Azithromycin
Participants will be shipped a single 1.2 g dose of oral azithromycin |
Placebo Comparator: Placebo
Matching placebo
|
Drug: Placebos
Participants will be shipped a dose of matching placebo |
- Number of Participants Who Were Symptom Free at Day 14 [ Time Frame: 14 days ]Binary assessment of whether the participant is experiencing any symptoms at Day 14 (yes or no)
- Viral Load - Nasal Swab [ Time Frame: 3 days ]Viral load by self-collected nasal swab
- Viral Load - Saliva Swab [ Time Frame: 3 days ]Viral load by self-collected saliva swab
- Mortality [ Time Frame: 14 days ]All-cause mortality
- Adverse Events [ Time Frame: 3 days ]Percentage of participants experiencing adverse events, including gastrointestinal side effects and rash
- Positive SARS-CoV-2 Test - Nasal Swab [ Time Frame: 3 days ]Prevalence of positive SARS-CoV-2 test by self-collected nasal swab
- Positive SARS-CoV-2 Test - Saliva Swab [ Time Frame: 3 days ]Prevalence of positive SARS-CoV-2 test by self-collected saliva swab
- Positive SARS-CoV-2 Test - Rectal Swab [ Time Frame: 3 days ]Prevalence of positive SARS-CoV-2 test by self-collected rectal swab
- Genetic Macrolide Resistance Determinants [ Time Frame: 3 days ]Prevalence of genetic macrolide resistance determinants by self-collected rectal swab
- Secondary Outcomes Through Day 21 [ Time Frame: Cumulative over 21 days reported (assessed at 3, 7, 14, 21 days) ]Prevalence of cough, fever, myalgia, anosmia, shortness of breath, fatigue, conjunctivitis, and orthostatic symptoms through Day 21
- Number of Participants With Emergency Room Visits [ Time Frame: 21 days ]Number of emergency room visits <24 hours
- Number of Household Members With COVID-19 (Confirmed or Symptomatic) [ Time Frame: 21 days ]Number of household members with confirmed or symptomatic COVID-19 through Day 21
- Number of Participants That Died [ Time Frame: 21 days ]Deaths within the study
- Number of Participants Reporting Hospitalization [ Time Frame: 21 Days ]Number of hospitalizations defined as a hospital stay or ER stay longer than 24 hours through 21 days post enrollment

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Evidence of a positive SARS-CoV-2 test and test results received within the previous seven days
- Not currently hospitalized
- Willing and able to receive study drug by mail
- Willing and able to do the study questionnaires at baseline, day 3, 7, 14, 21 days via email or over the phone
- No known allergy or other contraindication to macrolides
- Age 18 years or older at the time of enrollment
- No known history of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia)
- No recent use of hydroxychloroquine within the past 7 days for participants >55 years of age
- Not currently taking nelfinavir or warfarin (Coumadin)
- Provision of informed consent
- Not currently pregnant

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04332107
United States, California | |
University of California San Francisco | |
San Francisco, California, United States, 94143 |
Principal Investigator: | Catherine Oldenburg, ScD, MPH | University of California, San Francisco | |
Principal Investigator: | Thuy Doan, MD, PhD | University of California, San Francisco |
Documents provided by Thomas M. Lietman, University of California, San Francisco:
Responsible Party: | Thomas M. Lietman, Professor, University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT04332107 |
Other Study ID Numbers: |
20-30504 |
First Posted: | April 2, 2020 Key Record Dates |
Results First Posted: | September 9, 2021 |
Last Update Posted: | March 2, 2023 |
Last Verified: | February 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
COVID-19 Pneumonia, Viral Pneumonia Respiratory Tract Infections Infections Virus Diseases Coronavirus Infections Coronaviridae Infections |
Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Azithromycin Anti-Bacterial Agents Anti-Infective Agents |